Sonoma Pharmaceuticals
SNOA
18 hedge funds and large institutions have $860K invested in Sonoma Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.11% less ownership
Funds ownership: 0.39% → 0.29% (-0.11%)
10% less funds holding
Funds holding: 20 → 18 (-2)
27% less capital invested
Capital invested by funds: $1.19M → $860K (-$326K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$143K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$19.9K |
| 3 |
Morgan Stanley
New York
|
+$13K |
| 4 |
HFS
HBC Financial Services
Seattle,
Washington
|
+$1.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$152K |
| 2 |
VF
Virtu Financial
New York
|
-$119K |
| 3 |
Squarepoint
New York
|
-$88K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.52K |
| 5 |
RE
RBC Europe
London,
United Kingdom
|
-$6.21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $284K | -$152K | -1,420 | -31% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $250K | +$143K | +1,338 | +96% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $168K | – | – | – |
|
|
4
Dimensional Fund Advisors
Austin,
Texas
| $68K | +$19.9K | +186 | +33% |
|
|
HFS
5
HBC Financial Services
Seattle,
Washington
| $54K | +$1.92K | +18 | New |
|
6
BlackRock
New York
| $13K | – | – | – |
|
|
7
Morgan Stanley
New York
| $11K | +$13K | +122 | +2,440% |
|
|
8
UBS Group
Zurich,
Switzerland
| $7K | -$6.52K | -61 | -46% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $2K | -$4.81K | -45 | -63% |
|
10
US Bancorp
Minneapolis,
Minnesota
| $2K | – | – | – |
|
11
Osaic Holdings
Scottsdale,
Arizona
| $1K | – | – | – |
|
|
VF
12
Virtu Financial
New York
| – | -$119K | -1,063 | Closed |
|
|
13
Squarepoint
New York
| – | -$88K | -786 | Closed |
|
|
RE
14
RBC Europe
London,
United Kingdom
| – | -$6.21K | -56 | Closed |
|
SNOA Hedge Fund Activity: Q4 2021 in Review
18 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q4 2021, worth a combined $860K — down 27% from $1.19M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SNOA and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $143K. The largest seller was Renaissance Technologies, cutting an estimated $152K.
- 18 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q4 2021, down from 20 in Q3 2021.
- Funds reported $860K of Sonoma Pharmaceuticals stock for Q4 2021, down 27% quarter-over-quarter.
- 1 fund opened new Sonoma Pharmaceuticals positions in Q4 2021 and 3 closed out, a net change of -2 holders.
- The largest Sonoma Pharmaceuticals buyer in Q4 2021 was Vanguard Group, an estimated $143K added.
- The largest Sonoma Pharmaceuticals seller in Q4 2021 was Renaissance Technologies, an estimated $152K sold.
Based on aggregated 13F filings for Q4 2021.